Technical Analysis for ALNA - Allena Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Historical ALNA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Expansion Breakdown | Bearish Swing Setup | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 180 Bearish Setup | Bearish Swing Setup | -5.00% | |
| Wide Bands | Range Expansion | -5.00% | |
| Oversold Stochastic | Weakness | -5.00% | |
| Hammer Candlestick | Bullish | -8.80% | |
| Lizard Bullish | Bullish Day Trade Setup | -8.80% | |
| Pocket Pivot | Bullish Swing Setup | -8.80% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Fell Below Lower Bollinger Band | about 17 hours ago |
| Lower Bollinger Band Support | about 17 hours ago |
| Down 1 ATR | about 17 hours ago |
| Down 5% | about 18 hours ago |
| Down 3% | about 18 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 09/27/2019
Allena Pharmaceuticals, Inc. Description
Allena Pharmaceuticals, Inc. is a United States-based specialty biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones. ALLN-177 is an orally administered, recombinant oxalate-degrading enzyme. ALLN-177 targets oxalate in the gastrointestinal (GI) tract to reduce the burden of both dietary and endogenously produced oxalate. ALLN-177 has the potential to decrease the oxalate available systemically for deposition as calcium oxalate crystals or stones in the kidneys, as well as to reduce the incidence of calcium oxalate related complications. Its technological approach enables the design and development of oral protein therapies that remain in the GI tract.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Organ Systems Gastrointestinal Kidney Diseases Orphan Disease Orphan Diseases Crystals Hyperoxaluria
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.39 |
| 52 Week Low | 1.07 |
| Average Volume | 1,198,150 |
| 200-Day Moving Average | 1.48 |
| 50-Day Moving Average | 1.63 |
| 20-Day Moving Average | 1.38 |
| 10-Day Moving Average | 1.28 |
| Average True Range | 0.11 |
| ADX | 31.61 |
| +DI | 10.51 |
| -DI | 34.67 |
| Chandelier Exit (Long, 3 ATRs ) | 1.40 |
| Chandelier Exit (Short, 3 ATRs ) | 1.42 |
| Upper Bollinger Band | 1.67 |
| Lower Bollinger Band | 1.10 |
| Percent B (%b) | 0.06 |
| BandWidth | 40.52 |
| MACD Line | -0.11 |
| MACD Signal Line | -0.10 |
| MACD Histogram | -0.0142 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.38 | ||||
| Resistance 3 (R3) | 1.39 | 1.32 | 1.34 | ||
| Resistance 2 (R2) | 1.32 | 1.26 | 1.32 | 1.33 | |
| Resistance 1 (R1) | 1.23 | 1.22 | 1.20 | 1.22 | 1.31 |
| Pivot Point | 1.16 | 1.16 | 1.14 | 1.16 | 1.16 |
| Support 1 (S1) | 1.07 | 1.10 | 1.04 | 1.06 | 0.97 |
| Support 2 (S2) | 1.00 | 1.06 | 1.00 | 0.95 | |
| Support 3 (S3) | 0.91 | 1.00 | 0.94 | ||
| Support 4 (S4) | 0.90 |
